Research · 10 min read
How to Report a Side Effect, and What Happens to the Report
You can file it yourself, and nobody has to do it for you. FDA says in plain words that your health care provider is not required to report. The company's duty is narrower than most people assume, and for a compounded preparation it depends on which kind of pharmacy made it.
Key takeaways
- FDA states plainly that a health care provider is not required to report an adverse event, so you may need to file it yourself.
- The consumer reporting form is voluntary, and FDA says its surveillance relies on those voluntary reports.
- A company's 15-day alert report attaches only to an experience that is both serious and unexpected, where unexpected means not listed in the current labeling.
- Expected effects still get reported, on a slower schedule — quarterly for three years from approval, then annually.
- An outsourcing facility under section 503B has a statutory reporting duty and must put the MedWatch site and phone number on the container it describes.
- Section 503A contains no adverse-event reporting sentence; the word "adverse" appears once in that whole section, in the demonstrable-difficulties clause.
- The database is now called AEMS, formerly FAERS, and its own page says reports cannot establish causation or occurrence rates.
- Filing is not an admission of causation, which is what makes reporting workable in the first place.
Answer first: the report is yours to make
FDA runs a voluntary reporting program called MedWatch. Consumers, patients and health professionals can all file into it, and there is a consumer version of the form written for people who are not clinicians.
The agency's own consumer page states the thing most people get wrong. It encourages you to take the form to your doctor, because a clinician can add information from your medical record. Then it says plainly that your health care provider is not required to report to FDA, and that in that situation you may complete the online form yourself.
That single sentence changes how to think about the whole system. If you assume a report was filed because you told someone about a symptom, you may be assuming a duty that does not exist.
The page also says why the agency asks. In its words, to keep effective medical products available on the market, FDA relies on the voluntary reporting of these events, and uses the data to maintain safety surveillance.
What FDA means by serious, in its own words
The consumer page defines an adverse event as any undesirable experience associated with the use of a medical product in a patient. It then gives the outcomes that make one serious and worth reporting.
Death, where you suspect the death was an outcome of the event. Life-threatening, where the patient was at substantial risk of dying at the time. Hospitalization, either an admission or a prolonged stay, where the event caused it.
Disability or permanent damage, which the page describes as a substantial disruption of a person's ability to conduct normal life functions — a significant, persistent or permanent change in body function or structure, physical activity, or quality of life.
One line there is easy to miss and worth reading twice. An emergency room visit that does not end in admission should be evaluated against the other serious outcomes rather than treated as automatically not serious.
None of that is a threshold you have to clear before filing. The program takes reports of product quality problems, therapeutic failure and product use errors as well, and the definition above tells you which ones the agency treats as urgent.
The company's duty is narrower than the word 'report' suggests
For an FDA-approved drug, the duty sits on the application holder and is set by 21 CFR 314.80. The headline requirement is the 15-day alert report, and it attaches to an adverse drug experience that is both serious and unexpected, foreign or domestic, no later than 15 calendar days from the company's first receipt of the information.
Both words are load-bearing, and the second one is the surprise. The regulation defines an unexpected adverse drug experience as any adverse drug experience that is not listed in the current labeling for the drug product.
Read that against the labels in this category. Nausea, vomiting, diarrhea and constipation are listed. So a report of one of those is expected, whatever it felt like to the person who had it, and it does not trigger the 15-day clock.
Those reports do not vanish. They go into periodic reports, which the regulation requires quarterly for three years from approval and annually after that. The clock is slower, not absent.
The regulation also defines unexpected to cover greater severity or greater specificity than what the label describes. Its own example is that hepatic necrosis would be unexpected if the labeling only referred to elevated hepatic enzymes or hepatitis.
Where a compounded preparation sits, and the census behind that
There are two federal compounding sections, and on this question they do not match.
An outsourcing facility under section 503B has a statutory adverse-event reporting duty. The section states that outsourcing facilities shall submit adverse event reports to the Secretary in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305.
That regulation is the parallel of 314.80 for products without an approved application. Its scope covers manufacturers, packers and distributors of marketed prescription drug products that are not the subject of an approved new drug or abbreviated new drug application. The same 15-day clock applies to serious and unexpected experiences.
Section 503B goes further and puts the reporting address on the package. The container from which individual units are removed must carry, in the statute's own words, the following information to facilitate adverse event reporting: www.fda.gov/medwatch and 1–800–FDA–1088, or any successor site or number.
Section 503A, which covers traditional compounding by a pharmacy or a physician, contains no comparable sentence. That is a counted claim, not an impression. The word "adverse" appears exactly once in the full text of 21 U.S.C. 353a as published in the 2023 edition of the U.S. Code, and the one occurrence is inside the clause about drug products that present demonstrable difficulties for compounding. It is a limit on what may be compounded, not a duty to report anything.
This is a difference in federal duty, not a safety finding about any pharmacy. State pharmacy law governs a 503A pharmacy's practice, and nothing here says a given pharmacy does or does not report. It says which federal sentence exists and which one does not.
The database has a new name
The system that collected these reports was known for years as the FDA Adverse Event Reporting System, or FAERS. The public dashboard page now carries a different heading: the FDA Adverse Event Monitoring System, AEMS, with the parenthetical note that it was formerly FAERS.
The page describes AEMS as a consolidation of multiple separate reporting systems used across FDA-regulated product categories, from medical products and vaccines to devices, tobacco, food, cosmetics and veterinary medicines. It also says AEMS will handle consumer complaints and regulatory misconduct reports, not only adverse events.
This matters for a practical reason. If you go looking for what has been reported about a medication and search for the old acronym, you may land on redirected or older material. The current dashboard is the one that will answer the question.
What a report in that database can and cannot tell you
The dashboard page states its own limits, and they are unusually blunt for a government page. Four of them are worth carrying around.
Duplicate and incomplete reports are in the system. There are many instances of duplicative reports, and some reports do not contain all the necessary information.
The existence of a report does not establish causation. For any given report there is no certainty that a suspected drug caused the event, and the information reflects only the reporter's observations and opinions.
The information has not been verified. Submission of a report does not mean the content has been medically confirmed.
Rates of occurrence cannot be established from these reports. The data cannot be used to estimate how often an event happens.
The page adds one sentence aimed at readers rather than analysts: patients should talk to their doctor before stopping or changing how they take their medications. A count pulled from this database is a count of reports, and nothing more.
The disclaimer both regulations carry
Each of the two reporting regulations closes with the same idea, and it explains why a company files without conceding anything.
A report submitted under the section, and any release of it by FDA, does not necessarily reflect a conclusion. Neither the company nor FDA is treated as concluding that the report is an admission that the drug caused or contributed to an adverse effect. The company need not admit, and may deny, that it does.
That is the legal machinery that lets surveillance work at all. Reporting is not an admission, so there is no incentive to sit on a report while lawyers decide what it means.
It also sets the reader's expectation correctly. A filed report is an observation entering a pile of observations, and the pile is what gets analyzed.
What happens to your name
Both regulations address this in nearly identical language. A company should not include the names and addresses of individual patients, and should assign a unique code instead.
The reporter's name is different. The company should include the name of the reporter as part of the initial reporter information, even when the reporter is the patient.
Then the disclosure rule. The names of patients, health care professionals, hospitals and geographical identifiers in adverse drug experience reports are not releasable to the public under FDA's public information regulations in 21 CFR part 20.
Records are kept for a long time on the company side. Both sections require ten years of records of adverse drug experiences, including raw data and correspondence, open to an authorized FDA employee at reasonable times.
Practical order of operations
Tell whoever prescribed for you first, because clinical judgment about what is happening to you is not something a form provides. That is also the person who can add record detail to a report.
If a report is going to be filed, find out whether it was, rather than assuming. The provider has no federal obligation to file one.
Keep the physical evidence. Both regulations list lot number, expiration date and National Drug Code among the fields a report carries, and those live on the carton and the vial or pen, not in your memory.
If the product was compounded, note who compounded it and how the container was labeled. Section 503B requires the reporting website and phone number on the container it describes, which tells you something about what kind of facility produced it.
You can file with FDA yourself either way. The consumer form exists for exactly this, and the agency asks for the reports.
Sources
- 21 CFR 314.80 — Postmarketing reporting of adverse drug experiencesThe definitions of adverse drug experience, serious adverse drug experience and unexpected adverse drug experience, including the hepatic necrosis example of greater severity. Paragraph (c)(1)(i) for the 15-day alert report on experiences that are both serious and unexpected, foreign or domestic, within 15 calendar days of initial receipt. Paragraph (c)(2)(i) for quarterly periodic reports for three years from approval and annual reports after that. Paragraph (f)(3) for lot number, expiration date and National Drug Code among the fields a report carries. Paragraph (i) for patient privacy, the unique patient code, inclusion of the reporter's name even when the reporter is the patient, and the statement that names of patients, health care professionals, hospitals and geographical identifiers are not releasable under part 20. Paragraph (j) for the ten-year recordkeeping period. Paragraph (l) for the disclaimer that a report is not an admission of causation.
- 21 CFR 310.305 — Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applicationsParagraph (a) for the scope covering manufacturers, packers and distributors of marketed prescription drug products not the subject of an approved new drug or abbreviated new drug application. Paragraph (c)(1)(i) for the 15-day alert report on serious and unexpected experiences. Paragraph (f) for the patient-privacy language and the part 20 non-releasability of names. Paragraph (g)(1) for the ten-year record retention and (g)(3) for FDA access at reasonable times. Paragraph (h) for the disclaimer that a report is not an admission of causation. ⛔ The request was written against subpart-E and landed on subpart-D; the URL above is the one that rendered.
- 21 U.S.C. 353b — Outsourcing facilitiesSubsection (b)(5), stating that outsourcing facilities shall submit adverse event reports to the Secretary in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305. Subsection (a)(10)(B)(ii), requiring the container to carry www.fda.gov/medwatch and 1–800–FDA–1088, or any successor site or number, to facilitate adverse event reporting.
- 21 U.S.C. 353a — Pharmacy compoundingThe censused absence. The word "adverse" appears exactly once in the full text of this section, in the clause on drug products identified by the Secretary as presenting demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on safety or effectiveness. The section contains no adverse-event reporting requirement.
- Reporting Serious Problems to FDA — MedWatchThe description of MedWatch as FDA's program for reporting serious reactions, product quality problems, therapeutic inequivalence or failure, and product use errors. The verbatim statement that a health care provider is NOT required to report to the FDA, and that a consumer may complete the online reporting form. The statement that FDA relies on voluntary reporting to maintain safety surveillance. The existence of a consumer-friendly version of the reporting form.
- What is a Serious Adverse Event?The definition of an adverse event as any undesirable experience associated with the use of a medical product in a patient, and the serious outcomes: death, life-threatening, hospitalization initial or prolonged, and disability or permanent damage described as a substantial disruption of a person's ability to conduct normal life functions. Also the instruction that an emergency room visit not resulting in admission should be evaluated against the other serious outcomes.
- FDA Adverse Event Monitoring System (AEMS) Public DashboardThe rename, carried on the page as "[Formerly FDA Adverse Event Reporting System (FAERS)]", and the description of AEMS as a consolidation of separate reporting systems across FDA-regulated product categories including medical products, vaccines, devices, tobacco, food, cosmetics and veterinary medicines, extending to consumer complaints and regulatory misconduct reports. The four stated limitations: duplicate and incomplete reports, existence of a report not establishing causation, information not medically verified, and rates of occurrence not estimable. The sentence that patients should talk to their doctor before stopping or changing how they take their medications. ⛔ The FAERS URL requested redirected to this AEMS path; this is the URL that rendered.
Frequently asked questions
Does my doctor have to report a side effect I describe?
No. FDA's consumer page states it directly: your health care provider is NOT required to report to the FDA. The page encourages you to take the reporting form to a clinician because they can add information from your medical record, then says that if they do not complete it, you may complete the online form yourself. Mandatory reporting duties fall on companies — application holders under 21 CFR 314.80, and manufacturers, packers and distributors of unapproved marketed prescription drugs under 21 CFR 310.305.
Why would a company not have to report my nausea within 15 days?
Because the 15-day alert report attaches only to an experience that is both serious and unexpected. The regulation defines unexpected as not listed in the current labeling for the drug product. Common gastrointestinal effects are listed on these labels, so they are expected in the regulation's sense, and they go into periodic reports instead — quarterly for three years from approval, then annually. The word describes the label, not how surprising the experience was to you.
Is a compounded medication covered by any of this?
It depends on the section the pharmacy operates under. An outsourcing facility under section 503B is required by statute to submit adverse event reports in accordance with the requirements established under 21 CFR 310.305, and the container it describes must carry the MedWatch address and phone number. Section 503A, which covers traditional pharmacy compounding, contains no such sentence — the word "adverse" appears once in the whole section, in the clause about products that present demonstrable difficulties for compounding. That is a difference in federal duty, not a judgment about any pharmacy.
Can I look up what other people have reported?
Yes, through the public dashboard, which now sits under the name FDA Adverse Event Monitoring System (AEMS). The page notes that it was formerly the FDA Adverse Event Reporting System (FAERS). The dashboard lists its own limitations plainly. Duplicate and incomplete reports are in the system. The existence of a report does not establish causation. The information has not been medically verified. And rates of occurrence cannot be estimated from it.
Does filing a report mean someone decided the drug caused it?
No, and both regulations say so in a closing disclaimer. A report submitted under the section, and any release of it by FDA, does not necessarily reflect a conclusion. Neither the company nor FDA is treated as concluding that it is an admission that the drug caused or contributed to an adverse effect. The company need not admit it and may deny it. The dashboard page repeats the point for readers: the information in a report reflects only the reporter's observations and opinions.
Will my name end up in a public database?
The rule points the other way. Companies are told not to include patients' names and addresses and to assign a unique code instead. They are told to include the reporter's name in the initial reporter information, even when the reporter is the patient. Separately, the names of patients, health care professionals, hospitals and geographical identifiers in adverse drug experience reports are not releasable to the public under FDA's public information regulations in 21 CFR part 20.